Lincoln Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹191 Cr +17.2% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
LP

Lincoln Pharmaceuticals Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Lincoln Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹163Cr
+1.2% YoY
+5.8% QoQ
Net profit
₹20Cr
−23.1% YoY
−28.6% QoQ
Margin
16%
−2 pp YoY
+1 pp QoQ

Based on Lincoln Pharmaceuticals Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹595
Market cap₹1.2K Cr
P/E12.6

The short version

EBITDA: ₹2,927 Crore, a YoY increase of 10.4% - Operating Margin: 27.4%, a YoY improvement of 110 basis points (bps) - Profit After Tax (PAT): ₹1,852 Crore, a YoY growth of 16.7% - Margin Outlook: The

From Lincoln Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

See what Lincoln Pharmaceuticals Ltd said on revenue & sales performance — free account, 30 seconds.

Profitability & Margins

See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Lincoln Pharmaceuticals Ltd Q2 FY26 results — key figures

Lincoln Pharmaceuticals Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue163161+1.2%154+5.8%
Operating profit (EBITDA)2528-10.7%24+4.2%
Operating margin16%18%-2 pp15%+1 pp
Profit before tax2935-17.1%35-17.1%
Net profit (PAT)2026-23.1%28-28.6%
EPS (₹)9.9813.15-24.1%13.82-27.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lincoln Pharmaceuticals Ltd Q2 FY26 results?

EBITDA: ₹2,927 Crore, a YoY increase of 10.4% - Operating Margin: 27.4%, a YoY improvement of 110 basis points (bps) - Profit After Tax (PAT): ₹1,852 Crore, a YoY growth of 16.7% - Margin Outlook: The

What is Lincoln Pharmaceuticals Ltd share price analysis?

Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.